Patents by Inventor Michael A. Kuzyk
Michael A. Kuzyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8728823Abstract: A method is described for detecting lung cancer comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject at risk for developing lung cancer. Further, a method is described for predicting risk of developing lung cancer in a subject comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject. Additionally, a method of monitoring the success of lung cancer treatment is described comprising detecting levels of a CTAP III-related biomarker in a biological sample from a subject undergoing treatment for lung cancer for comparison with a previous level obtained from the subject. Multivariate analysis may be incorporated into these methods, evaluating such clinical, or demographic risk factors as age, sex, smoking history, smoking status, smoking family history, education level, COPD, socio-economic status, body mass index and lung function. Kits for conducting such methods are described.Type: GrantFiled: November 24, 2008Date of Patent: May 20, 2014Assignee: British Columbia Cancer Agency BranchInventors: Stephen Lam, John Yee, Michael Kuzyk, Don Sin, Marianne Dorthy Sadar, Carl Martin Tammemagi
-
Patent number: 7851197Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: GrantFiled: July 8, 2009Date of Patent: December 14, 2010Assignee: Universitat BernInventors: Joachim Frey, Peter Kuhnert, Julian C. Thornton, Tracy A. Thornton, legal representative, Michael A. Kuzyk, Jan Burian, Martin Braun
-
Patent number: 7815896Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: GrantFiled: March 4, 2009Date of Patent: October 19, 2010Assignee: Universitat BernInventors: Joachim Frey, Katja Stuber, Julian C. Thornton, Michael A. Kuzyk, Jan Burian
-
Publication number: 20100248290Abstract: A method is described for detecting lung cancer comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject at risk for developing lung cancer. Further, a method is described for predicting risk of developing lung cancer in a subject comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject. Additionally, a method of monitoring the success of lung cancer treatment with curative intent is described comprising detecting levels of a CTAP III-related biomarker in a biological sample from a subject undergoing treatment for lung cancer for comparison with the a previous level obtained from the subject. Multivariate analysis may be incorporated into these methods, evaluating such clinical, or demographic risk factors as age, sex, smoking history, smoking status, smoking family history, education level, COPD, socio-economic status, body mass index and lung function. Kits for conducting such methods are described.Type: ApplicationFiled: November 24, 2008Publication date: September 30, 2010Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Stephen Lam, John Yee, Michael Kuzyk, Don Sin, Marianne Dorthy Sadar, Carl Martin Tammemagi
-
Publication number: 20100008895Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: ApplicationFiled: July 8, 2009Publication date: January 14, 2010Applicant: UNIVERSITAT BERNInventors: JOACHIM FREY, PETER KUHNERT, JULIAN C. THORNTON, TRACY A. THORNTON, MICHAEL A. KUZYK, JAN BURIAN, MARTIN BRAUN
-
Publication number: 20090226462Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: ApplicationFiled: March 4, 2009Publication date: September 10, 2009Inventors: Joachim Frey, Katja Stuber, Julian C. Thornton, Michael A. Kuzyk, Jan Burian
-
Patent number: 7579011Abstract: A novel protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: GrantFiled: December 14, 2006Date of Patent: August 25, 2009Assignee: Universitat BernInventors: Joachim Frey, Peter Kuhnert, Julian C. Thornton, Tracy A. Thornton, legal representative, Michael A. Kuzyk, Jan Burian, Martin Braun
-
Patent number: 7538208Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: GrantFiled: September 29, 2006Date of Patent: May 26, 2009Assignee: Universitat BernInventors: Joachim Frey, Katja Stuber, Julian C. Thornton, Michael A. Kuzyk, Jan Burian
-
Publication number: 20090074817Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: ApplicationFiled: September 29, 2006Publication date: March 19, 2009Inventors: Joachim Frey, Katja Stuber, Julian C. Thornton, Michael A. Kuzyk, Jan Burian
-
Patent number: 7351550Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AcxT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: GrantFiled: November 15, 2001Date of Patent: April 1, 2008Assignee: Universitat BernInventors: Joachim Frey, Peter Kuhnert, Tracy A. Thornton, legal representative, Michael A. Kuzyk, Jan Burian, Martin Braun, Julian C. Thornton
-
Publication number: 20070269462Abstract: A novel protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: ApplicationFiled: December 14, 2006Publication date: November 22, 2007Inventors: Joachim Frey, Peter Kuhnert, Julian Thornton, Tracy Thornton, Michael Kuzyk, Jan Burian, Martin Braun
-
Patent number: 7232569Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: GrantFiled: March 26, 2004Date of Patent: June 19, 2007Assignee: Universität BernInventors: Joachim Frey, Katja Stuber, Julian C. Thornton, Michael A. Kuzyk, Jan Burian
-
Publication number: 20050158344Abstract: A protein toxin named Aeromonas salmonicida exoenzyme T (AcxT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity against A. salmonicida infections.Type: ApplicationFiled: November 15, 2001Publication date: July 21, 2005Inventors: Joachim Frey, Peter Kuhnert, Julian Thornton, Tracy Thornton, Michael Kuzyk, Jan Burian, Martin Braun
-
Publication number: 20050058662Abstract: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.Type: ApplicationFiled: March 26, 2004Publication date: March 17, 2005Inventors: Joachim Frey, Katja Stuber, Julian Thornton, Michael Kuzyk, Jan Burian
-
Publication number: 20050002946Abstract: The use of the 17 kDa outer surface lipoprotein (OspA) of Piscirickettsia salmonis, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen P. salmonis are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of P. salmonis, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against P. salmonis and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA.Type: ApplicationFiled: February 18, 2004Publication date: January 6, 2005Inventors: Michael Kuzyk, Jan Burian, William Kay, Julian Thornton
-
Publication number: 20040086524Abstract: The use of the 17 kDa outer surface lipoprotein (OspA) of Piscirickettsia salmonis, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen P. salmonis are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of P. salmonis, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against P. salmonis and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA.Type: ApplicationFiled: September 30, 2002Publication date: May 6, 2004Inventors: Michael A. Kuzyk, Jan Burian, William W. Kay, Julian C. Thornton
-
Publication number: 20030165526Abstract: The use of the 17 kDa outer surface lipoprotein (OspA) of Piscirickettsia salmonis, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen P. salmonis are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of P. salmonis, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against P. salmonis and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA.Type: ApplicationFiled: September 30, 2002Publication date: September 4, 2003Inventors: Michael A. Kuzyk, Jan Burian, William W. Kay, Julian C. Thornton